SNGX Pengajuan SEC - Soligenix, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	549300MN2EF9LQHLT817
CIK	812796

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Soligenix, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 18, 2025	EX-99.1	FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet’s Disease after Reviewing Recent Phase 2 Clinical Study Results Provides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval EXHIBIT 99.1 FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet’s Disease after Reviewing Recent Phase 2 Clinical Study Results Provides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, NJ – August 18, 2025 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing pro
August 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 18, 2025 Commission File N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 18, 2025 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of inc
August 15, 2025	424B3	Up to 1,054,688 Shares of Common Stock Issuable Upon the Exercise of Previously Issued Common Warrants Prospectus Supplement No. 1 (To Prospectus dated March 21, 2025) Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-280993 Up to 1,054,688 Shares of Common Stock Issuable Upon the Exercise of Previously Issued Common Warrants This Prospectus Supplement No. 1 (this “Prospectus Supplement”) supplements the prospectus dated March 21, 2025 (the “Final Prospectus”), relating to the resale
August 15, 2025	424B3	4,253 shares of Common Stock Underlying Previously Issued Common Warrants Prospectus Supplement No. 1 (To Prospectus dated March 21, 2025) Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-276511 4,253 shares of Common Stock Underlying Previously Issued Common Warrants This Prospectus Supplement No. 1 (this “Prospectus Supplement”) supplements the prospectus dated March 21, 2025 (the “Final Prospectus”), relating to the offer and sale by us of 4,253 shares
August 15, 2025	424B3	408,640 shares of Common Stock Underlying Previously Issued Common Warrants Prospectus Supplement No. 1 (To Prospectus dated March 21, 2025) Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-271049 408,640 shares of Common Stock Underlying Previously Issued Common Warrants This Prospectus Supplement No. 1 (this “Prospectus Supplement”) supplements the prospectus dated March 21, 2025 (the “Final Prospectus”), relating to the offer and sale by us of 408,640 sh
August 15, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2025 Commission File N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2025 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of inc
August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 ☐TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14778 SOLIGENIX
August 14, 2025	EX-10.1	Consulting Agreement effective as of August 16, 2025 between Soligenix, Inc. and Richard Straube, MD.* EXHIBIT 10.1 CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) shall be effective as of August 16, 2025 by and between Richard Straube, M.D., M.Sc. (“Consultant”), having a residential address at 2207 Milford Warren Glen Road, Bloomsbury, NJ 08804, and Soligenix Inc., a Delaware corporation (“Company”). Now, therefore, Consultant and Company agree as follows: 1.Engagement. Company hereb
July 31, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 31, 2025 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) delaware 41-1505029 (State or other jurisdiction of incor
July 31, 2025	EX-99.1	Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet’s Disease Study results support advancing SGX945 in this difficult to treat orphan disease Exhibit 99.1 Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet’s Disease Study results support advancing SGX945 in this difficult to treat orphan disease Princeton, NJ – July 31, 2025 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare di
June 20, 2025	EX-FILING FEES	Calculation of Filing Fee Table. * EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Soligenix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Proposed Fee Maximum Maximum Amount of Security Security Class Calculation Amount Offering Price Aggregate Registration Type Title Rule Registered(1)(2) per Unit Offering Price Fee Rate Fee Equity Common stock, par value $0.0
June 20, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 20, 2025 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incor
June 20, 2025	S-8	As filed with the Securities and Exchange Commission on June 20, 2025. As filed with the Securities and Exchange Commission on June 20, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLIGENIX, INC. (Exact name of registrant as specified in its charter) Delaware 41-1505029 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer
June 20, 2025	EX-10.3	Form of Restricted Stock Agreement for 2025 Plan EXHIBIT 10.3 SOLIGENIX, INC. Restricted Stock Purchase Agreement Granted Under the 2025 Equity Incentive Plan THIS RESTRICTED STOCK PURCHASE AGREEMENT (this “Agreement”) made this day of , 20, between Soligenix Inc., a Delaware corporation (the “Company”), and (the “Holder”). This Agreement is subject to the provisions of the Company’s 2025 Equity Incentive Plan (the “Plan”), a copy of which is fu
June 20, 2025	EX-10.1	Soligenix, Inc. 2025 Equity Incentive Plan EXHIBIT 10.1 SOLIGENIX, INC. 2025 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS ON MAY 5, 2025 The purpose of the Soligenix, Inc. 2025 Equity Incentive Plan (the “Plan”) is to advance the interests of Soligenix, Inc. by enhancing its ability to attract and retain employees and other persons who can make significant contributions to the success of the Company through ownership of shares o
June 20, 2025	EX-10.2	Form of Stock Option Agreement for 2025 Plan EXHIBIT 10.2 NOTICE OF GRANT OF STOCK OPTION Notice is hereby given of the following option grant (the “Option”) to purchase shares of the Common Stock of Soligenix, Inc. (the “Corporation”): Optionee: [NAME] Grant Date: [DATE] Vesting Commencement Date: [DATE] Exercise Price: $[PRICE] per share Number of Option Shares: [NUMBER] shares Expiration Date: [DATE] Type of Option: (check as appropriate)
May 9, 2025	EX-10.1	Fourth Amendment to Employment Agreement dated as of May 5, 2025, between Soligenix, Inc. and Christopher J. Schaber, PhD. EXHIBIT 10.1 FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT This Fourth Amendment to Employment Agreement (the “Amendment”) is made and entered into as of May 5, 2025 by and between Soligenix, Inc., a Delaware corporation having a place of business at 29 Emmons Drive, Suite B-10, Princeton, NJ 08540 (the “Corporation”), and Christopher J. Schaber, Ph.D. (the “Employee”). RECITALS WHEREAS, the Corporatio
May 9, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 ☐TRANSITION REPORT PURSUANT TO SE Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14778 SOLIGENI
May 5, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive
May 5, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(
March 28, 2025	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 25, 2025 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of inco
March 28, 2025	EX-3.1	Second Amended and Restated Bylaws of Soligenix, Inc. effective as of March 25, 2025 EXHIBIT 3.1 SECOND AMENDED AND RESTATED BY-LAWS OF SOLIGENIX, INC. ADOPTED AS OF MARCH 25, 2025 ARTICLE I OFFICES SECTION 1.1. REGISTERED OFFICE. The registered office of Soligenix, Inc. (the “CORPORATION”) shall be in the City of Wilmington, County of New Castle, State of Delaware. SECTION 1.2. OTHER OFFICES. The Corporation may also have offices at such other places both within and without the S
March 21, 2025	EX-21.1	Subsidiaries of the Company. *** EXHIBIT 21.1 SUBSIDIARIES OF SOLIGENIX, INC. The following represents a list of Soligenix, Inc.’s subsidiaries: Name Ownership State of Incorporation Enteron Pharmaceuticals, Inc. 100.00 % Delaware Orasomal Technologies Inc. 75.30 % Delaware Soligenix BioPharma Canada Incorporated 100.00 % Canada Soligenix UK Limited 100.00 % United Kingdom Soligenix NE B.V. 100.00 % Netherlands Soligenix Biopharm
March 21, 2025	POS AM	As filed with the Securities and Exchange Commission on March 21, 2025. Table of Contents As filed with the Securities and Exchange Commission on March 21, 2025.
March 21, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Fiscal Year Ended December 31, 2024 ☐TRANSITION REPORT PURSUAN Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Fiscal Year Ended December 31, 2024 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File No. 001-14778 SOL
March 21, 2025	EX-21.1	Subsidiaries of the Company. *** EXHIBIT 21.1 SUBSIDIARIES OF SOLIGENIX, INC. The following represents a list of Soligenix, Inc.’s subsidiaries: Name Ownership State of Incorporation Enteron Pharmaceuticals, Inc. 100.00 % Delaware Orasomal Technologies Inc. 75.30 % Delaware Soligenix BioPharma Canada Incorporated 100.00 % Canada Soligenix UK Limited 100.00 % United Kingdom Soligenix NE B.V. 100.00 % Netherlands Soligenix Biopharm
March 21, 2025	EX-21.1	Subsidiaries of the Company. *** EXHIBIT 21.1 SUBSIDIARIES OF SOLIGENIX, INC. The following represents a list of Soligenix, Inc.’s subsidiaries: Name Ownership State of Incorporation Enteron Pharmaceuticals, Inc. 100.00 % Delaware Orasomal Technologies Inc. 75.30 % Delaware Soligenix BioPharma Canada Incorporated 100.00 % Canada Soligenix UK Limited 100.00 % United Kingdom Soligenix NE B.V. 100.00 % Netherlands Soligenix Biopharm
March 21, 2025	EX-4.1	Description of Securities. * EXHIBIT 4.1 SOLIGENIX, INC. DESCRIPTION OF SECURITIES The following description of the terms of our securities is not complete and is qualified in its entirety by reference to our Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and our Bylaws, as amended (the “Bylaws”), both of which are filed as exhibits to our Annual Reports on Form 10-K. Under our Certificate of In
March 21, 2025	EX-21.1	Subsidiaries of the Company. * EXHIBIT 21.1 SUBSIDIARIES OF SOLIGENIX, INC. The following represents a list of Soligenix, Inc.’s subsidiaries: Name Ownership State of Incorporation Enteron Pharmaceuticals, Inc. 100.00 % Delaware Orasomal Technologies Inc. 75.30 % Delaware Soligenix BioPharma Canada Incorporated 100.00 % Canada Soligenix UK Limited 100.00 % United Kingdom Soligenix NE B.V. 100.00 % Netherlands Soligenix Biopharm
March 21, 2025	POS AM	As filed with the Securities and Exchange Commission on March 21, 2025. Table of Contents As filed with the Securities and Exchange Commission on March 21, 2025.
March 21, 2025	POS AM	As filed with the Securities and Exchange Commission on March 21, 2025. As filed with the Securities and Exchange Commission on March 21, 2025. Registration No. 333-271049 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLIGENIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 41-1505029 (State or Other Jurisdiction of I
February 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2025 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2025 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of in
November 8, 2024	424B3	Up to 1,054,688 Shares of Common Stock Issuable Upon the Exercise of Previously Issued Common Warrants Prospectus Supplement No. 2 (To Prospectus dated July 24, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-280993 Up to 1,054,688 Shares of Common Stock Issuable Upon the Exercise of Previously Issued Common Warrants This Prospectus Supplement No. 2 (this “Prospectus Supplement”) supplements the prospectus dated July 24, 2024 (the “Final Prospectus”), relating to the resale fr
November 8, 2024	424B3	4,253 shares of Common Stock Underlying Previously Issued Common Warrants Prospectus Supplement No. 3 (To Prospectus dated April 17, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-276511 4,253 shares of Common Stock Underlying Previously Issued Common Warrants This Prospectus Supplement No. 3 (this “Prospectus Supplement”) supplements the prospectus dated April 17, 2024 (the “Final Prospectus”), relating to the offer and sale by us of 4,253 shares
November 8, 2024	424B3	Up to $5,800,000 of shares of Common Stock Prospectus Supplement No. 2 (To Prospectus dated December 15, 2023) Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-274265 Up to $5,800,000 of shares of Common Stock This Prospectus Supplement No. 2 (this “Prospectus Supplement”) supplements the prospectus dated December 15, 2023 (the “Final Prospectus”), relating to the offer and sale by us of up to $5,800,000 shares of our common
November 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14778 SOLI
October 11, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 8, 2024 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of inc
October 11, 2024	EX-10.1	Amendment to Loan and Security Agreement dated as of October 8, 2024 (incorporated by reference to Exhibit 10.1 included in our current report on Form 8-K filed on October 11, 2024). EXHIBIT 10.1 SECOND AMENDMENT TO THE LOAN AGREEMENT This Second Amendment (the “Second Amendment”) to the Loan and Security Agreement, dated as of December 15, 2020, as amended by the First Amendment dated April 19, 2023 (as amended, the “Agreement”) is made and entered into on October 8, 2024 (the “Effective Date”) by and between Soligenix, Inc., a corporation incorporated in the State of Delawar
August 16, 2024	EX-10.1	At Market Issuance Sales Agreement dated August 16, 2024 between Soligenix, Inc. and A.G.P./Alliance Global Partners (incorporated by reference to Exhibit 10.1 included in our current report on Form 8-K filed on August 16, 2024). EXHIBIT 10.1 SOLIGENIX, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement August 16, 2024 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 Ladies and Gentlemen: Soligenix, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (“AGP”) as follows: 1. Issuance and Sa
August 16, 2024	424B5	Up to $5,800,000 Soligenix, Inc. COMMON STOCK Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-274265 PROSPECTUS SUPPLEMENT (To prospectus dated December 15, 2023) Up to $5,800,000 Soligenix, Inc. COMMON STOCK We have entered into an At Market Issuance Sales Agreement (the “sales agreement”) with A.G.P./Alliance Global Partners (“A.G.P.” or the “sales agent”), dated August 16, 2024, relating to shares of our common stoc
August 16, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 16, 2024 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of inc
August 9, 2024	424B3	7,042,000 shares of Common Stock Underlying Previously Issued Pre-Funded Warrants 11,875,000 shares of Common Stock Underlying Previously Issued Common Warrants Prospectus Supplement No. 2 (To Prospectus dated April 17, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-276511 7,042,000 shares of Common Stock Underlying Previously Issued Pre-Funded Warrants 11,875,000 shares of Common Stock Underlying Previously Issued Common Warrants This Prospectus Supplement No. 2 (this “Prospectus Supplement”) supplements the prospectus dated April
August 9, 2024	424B3	Up to 1,054,688 Shares of Common Stock Issuable Upon the Exercise of Previously Issued Common Warrants Prospectus Supplement No. 1 (To Prospectus dated July 24, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-280993 Up to 1,054,688 Shares of Common Stock Issuable Upon the Exercise of Previously Issued Common Warrants This Prospectus Supplement No. 1 (this “Prospectus Supplement”) supplements the prospectus dated July 24, 2024 (the “Final Prospectus”), relating to the resale fr
August 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14778 SOLIGENIX
July 30, 2024	CORRESP	Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 July 30, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Soligenix, Inc. Registration Statement on Form S-1 File No. 333-280993 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Soligenix, Inc. (the “C
July 25, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 24, 2024 Commission File No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 24, 2024 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incor
July 24, 2024	EX-21.1	Subsidiaries of the Company. * Exhibit 21.1 SUBSIDIARIES OF SOLIGENIX, INC. The following represents a list of Soligenix, Inc.’s subsidiaries: Name Ownership State of Incorporation Enteron Pharmaceuticals, Inc. 100.00 % Delaware Orasomal Technologies Inc. 75.30 % Delaware Soligenix BioPharma Canada Incorporated 100.00 % Canada Soligenix UK Limited 100.00 % United Kingdom Soligenix NE B.V. 100.00 % Netherlands Soligenix Biopharm
July 24, 2024	EX-FILING FEES	Filing Fee Table. * Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Soligenix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount Registered Maximum Aggregate Offering Price (1) Fee Rate Amount of Registration Fee Fees to be Paid Equity Common Stock issuable upon exercise of Common Warrants 45
July 24, 2024	S-1	As filed with the Securities and Exchange Commission on July 24, 2024. Table of Contents As filed with the Securities and Exchange Commission on July 24, 2024.
July 9, 2024	EX-10.2	Financial Advisory Agreement, dated as of July 9, 2024, between A.G.P./Alliance Global Partners and the Company. July 9, 2024 CONFIDENTIAL Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Attention: Dr. Christopher J. Schaber Ph.D., CEO Re: Soligenix, Inc.– Financial Advisory Agreement Dear Dr. Schaber, The purpose of this letter (this “Agreement”) is to confirm the engagement of A.G.P./Alliance Global Partners (“A.G.P.”) by Soligenix, Inc., a Delaware corporation (the “Company”), to render Fi
July 9, 2024	EX-4.1	Form of Warrant to Purchase Shares of Common Stock issued in connection with July 2024 warrant inducement agreement (incorporated by reference to Exhibit 4.1 included in our current report on Form 8-K filed on July 9, 2024). EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
July 9, 2024	EX-10.1	Form of Warrant Inducement Agreement, by and between the Company and each Holder (incorporated by reference to Exhibit 10.1 included in our current report on Form 8-K filed on July 9, 2024). EXHIBIT 10.1 SOLIGENIX, INC. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 July 9, 2024 To the Holder of April 2024 Common Stock Purchase Warrants Re: Inducement Offer to Exercise Existing Common Stock Purchase Warrants Dear Holder: SOLIGENIX, INC. (the “Company”) is pleased to offer (this “Inducement Offer”) to you (“Holder”, “you” or similar terminology) the opportunity to receive new warrants
July 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2024 Commission File No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2024 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incorp
May 31, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 30, 2024 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incorp
May 31, 2024	EX-3.1	Certificate of Amendment to Second Amended and Restated Certificate of Incorporation of Soligenix, Inc. (incorporated by reference to Exhibit 3.1 included in our current report on Form 8-K filed on May 31, 2024). EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION THE UNDERSIGNED, being a duly appointed officer of Soligenix, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the Delaware General Corporation Law of the State of Delaware (the “DGCL”), for the purpose of amending the Corporation’s Second Amended and Restated Certi
May 31, 2024	EX-99.1	Soligenix Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 EXHIBIT 99.1 Soligenix Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on June 6, 2024 PRINCETON, NJ – May 31, 2024 – Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it intends to
May 29, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
May 28, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
May 24, 2024	EX-99.1	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting EXHIBIT 99.1 Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting Princeton, NJ – May 24, 2024 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2024 Annual Meeting of
May 24, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 23, 2024 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incorp
May 22, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
May 17, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 17, 2024 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incorp
May 17, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
May 15, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
May 10, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐TRANSITION REPORT PURSUANT TO SE Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14778 SOLIGENI
May 10, 2024	424B3	7,042,000 shares of Common Stock Underlying Previously Issued Pre-Funded Warrants 11,875,000 shares of Common Stock Underlying Previously Issued Common Warrants Prospectus Supplement (To Prospectus dated April 17, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No.
April 29, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(
April 22, 2024	EX-99.1	Soligenix Announces Pricing of $4.75 Million Public Offering EXHIBIT 99.1 Soligenix Announces Pricing of $4.75 Million Public Offering PRINCETON, N.J., April 18, 2024 Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 11,875,000 shares of commo
April 22, 2024	EX-4.1	Form of Pre-Funded Warrant issued in April 2024 public offering (incorporated by reference to Exhibit 4.1 included in our current report on Form 8-K filed on April 22, 2024). EXHIBIT 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK SOLIGENIX, INC. Warrant Shares: Original Issuance Date: April 22, 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any t
April 22, 2024	EX-10.1	Placement Agency Agreement dated April 17, 2024. EXHIBIT 10.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 April 17, 2024 Soligenix, Inc. Attention: Christopher J. Schaber, President and Chief Executive Officer 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Re: Placement Agency Agreement Dear Dr. Schaber: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance G
April 22, 2024	EX-10.2	Securities Purchase Agreement dated April 17, 2024 (incorporated by reference to Exhibit 10.2 included in our current report on Form 8-K filed on April 22, 2024). EXHIBIT 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 17, 2024, between Soligenix, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set for
April 22, 2024	EX-4.2	Form of Common Warrant issued in April 2024 public offering (incorporated by reference to Exhibit 4.2 included in our current report on Form 8-K filed on April 22, 2024). EXHIBIT 4.2 WARRANT TO PURCHASE SHARES OF COMMON STOCK SOLIGENIX, INC. Warrant Shares: Original Issuance Date: April 22, 2024 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the da
April 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 17, 2024 Commission File No UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 17, 2024 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of inco
April 19, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(
April 19, 2024	424B4	3,275,000 Shares of Common Stock Pre-Funded Warrants to Purchase 8,600,000 Shares of Common Stock Common Warrants to Purchase 11,875,000 Shares of Common Stock 8,600,000 shares of Common Stock Underlying the Pre-Funded Warrants 11,875,000 shares of C Prospectus Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-276511 3,275,000 Shares of Common Stock Pre-Funded Warrants to Purchase 8,600,000 Shares of Common Stock Common Warrants to Purchase 11,875,000 Shares of Common Stock 8,600,000 shares of Common Stock Underlying the Pre-Funded Warrants 11,875,000 shares of Common Stock Underlying the Common Warrants We are offering 3,275,000
April 15, 2024	CORRESP	Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 April 15, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Soligenix, Inc. Registration Statement on Form S-1 File No. 333-276511 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Soligenix, Inc. (the “
April 15, 2024	CORRESP	A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 15, 2024 CORRESP 1 filename1.htm A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 15, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Soligenix, Inc. Registration Statement on Form S-1, as amended File No: 333-276511 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Sec
April 3, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 3, 2024 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incor
April 3, 2024	EX-99.1	Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, EXHIBIT 99.1 Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study Princeton, NJ – April 3, 2024 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a lat
April 3, 2024	CORRESP	Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 April 3, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Soligenix, Inc. Withdrawal of Request for Acceleration of Effectiveness of Registration Statement Registration Statement on Form S-1, as amended Commission File No. 333-276511 Ladies and
April 3, 2024	EX-99.2	Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial p Exhibit 99.2 Rising to the Challenges of Rare Disease Treatment NASDAQ: SNGX April 03, 2024 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products and produ
April 2, 2024	CORRESP	Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 April 2, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Soligenix, Inc. Registration Statement on Form S-1 File No. 333-276511 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Soligenix, Inc. (the “C
April 2, 2024	CORRESP	A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 2, 2024 A.G.P. / Alliance Global Partners 590 Madison Ave., 28th Floor New York, NY 10022 April 2, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Soligenix, Inc. Registration Statement on Form S-1, as amended File No: 333-276511 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as a
April 2, 2024	S-1/A	As filed with the Securities and Exchange Commission on April 2, 2024. Table of Contents As filed with the Securities and Exchange Commission on April 2, 2024.
March 15, 2024	EX-97	Incentive Compensation Recoupment Policy. * Exhibit 97 SOLIGENIX, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1. Introduction. The Board of Directors (the “Board”) of Soligenix, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Boar
March 15, 2024	S-1/A	As filed with the Securities and Exchange Commission on March 15, 2024. Table of Contents As filed with the Securities and Exchange Commission on March 15, 2024.
March 15, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Fiscal Year Ended December 31, 2023 ☐TRANSITION REPORT PURSUAN Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Fiscal Year Ended December 31, 2023 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File No. 001-14778 SOL
March 15, 2024	EX-19.1	Insider Trading Policy. * Exhibit 19.1 ADMINISTRATIVE POLICY INSIDER TRADING ADM 1100 REVISION DATE: May 18, 2021 I. PURPOSE The following is the insider trading policy of Soligenix, Inc. and Subsidiaries (the "Company") and outlines the procedures that all Company personnel must follow. This policy and these procedures arise from the Company’s responsibilities as a publicly-traded entity. Failure to comply with these proc
March 15, 2024	EX-21.1	Subsidiaries of the Company. * EXHIBIT 21.1 SUBSIDIARIES OF SOLIGENIX, INC. The following represents a list of Soligenix, Inc.’s subsidiaries: Name Ownership State of Incorporation Enteron Pharmaceuticals, Inc. 100.00 % Delaware Orasomal Technologies Inc. 75.30 % Delaware Soligenix BioPharma Canada Incorporated 100.00 % Canada Soligenix UK Limited 100.00 % United Kingdom Soligenix NE B.V. 100.00 % Netherlands Soligenix Biopharm
March 15, 2024	EX-4.1	Description of Securities. * EXHIBIT 4.1 SOLIGENIX, INC. DESCRIPTION OF SECURITIES The following description of the terms of our securities is not complete and is qualified in its entirety by reference to our Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and our Bylaws, as amended (the “Bylaws”), both of which are filed as exhibits to our Annual Reports on Form 10-K. Under our Certificate of In
January 16, 2024	EX-4.2	Form of Common Warrant. * EXHIBIT 4.2 WARRANT TO PURCHASE SHARES OF COMMON STOCK SOLIGENIX, INC. Warrant Shares: Original Issuance Date: [•], 2024 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he
January 16, 2024	EX-FILING FEES	Filing Fee Table. * Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Soligenix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1) Fee Rate Amount of Registration Fee Fees to be paid Equity Common Stock (2)
January 16, 2024	EX-4.4	Form of Securities Purchase Agreement. * EXHIBIT 4.4 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of [·], 2024, between Soligenix, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in
January 16, 2024	EX-4.3	Form of Pre-Funded Warrant. * EXHIBIT 4.3 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK SOLIGENIX, INC. Warrant Shares: Original Issuance Date: [•], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o
January 16, 2024	EX-1.1	Form of Placement Agent Agreement. * EXHIBIT 1.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 [•], 2024 Soligenix, Inc. Attention: Christopher J. Schaber, President and Chief Executive Officer 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Re: Placement Agency Agreement Dear Dr. Schaber: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global
January 16, 2024	EX-21.1	Subsidiaries of the Company. * EXHIBIT 21.1 SUBSIDIARIES OF SOLIGENIX, INC. The following represents a list of Soligenix, Inc.’s subsidiaries: Name Ownership State of Incorporation Enteron Pharmaceuticals, Inc. 100.00 % Delaware Orasomal Technologies Inc. 75.30 % Delaware Soligenix BioPharma Canada Incorporated 100.00 % Canada Soligenix UK Limited 100.00 % United Kingdom Soligenix NE B.V. 100.00 % Netherlands Soligenix Biopharm
January 16, 2024	S-1	As filed with the Securities and Exchange Commission on January 12, 2024. As filed with the Securities and Exchange Commission on January 12, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLIGENIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 41-1505029 (State or Other Jurisdiction of Incorporation or Organization) (Primary
December 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2023 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
December 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 15, 2023 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 15, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
December 14, 2023	CORRESP	Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 December 14, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Soligenix, Inc. Registration Statement on Form S-3 Commission File No. 333-274265 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Soligeni
December 8, 2023	S-3/A	As filed with the Securities and Exchange Commission on December 8, 2023 As filed with the Securities and Exchange Commission on December 8, 2023 Registration No.
December 6, 2023	CORRESP	Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 December 6, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Soligenix, Inc. Registration Statement on Form S-3 Commission File No. 333-274265 Ladies and Gentlemen: Reference is made to our letter, filed as correspondence via EDGAR on November 3
November 30, 2023	CORRESP	Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 November 30, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 333-271049 Re: Soligenix, Inc. Registration Statement on Form S-3 File No. 333-274265 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Soligeni
November 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2023 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
November 17, 2023	EX-99.1	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting EXHIBIT 99.1 Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting Princeton, NJ – November 17, 2023 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeti
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14778 SOLI
October 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 18, 2023 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 18, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of in
October 20, 2023	EX-99.1	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting EXHIBIT 99.1 Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting Princeton, NJ – October 20, 2023 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meetin
October 17, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
October 17, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
October 16, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
October 13, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
October 12, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
October 12, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
September 22, 2023	EX-99.1	Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders EXHIBIT 99.1 Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by Stockholders Princeton, NJ – September 22, 2023 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unme
September 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 21, 2023 Commission Fil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 21, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of
September 22, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
September 15, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
September 15, 2023	EX-16.1	Letter from EisnerAmper LLP dated September 15, 2023 EXHIBIT 16.1 September 15, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K dated September 15, 2023 of Soligenix, Inc. and are in agreement with the statements contained therein as it regards our firm. We have no basis to agree or disagree with other statements of the registrant contained in Item 4.01. Sincere
September 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 15, 2023 Commission Fil UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 15, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of
August 30, 2023	EX-FILING FEES	Calculation of Filing Fee Table. ** Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Soligenix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(2) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee
August 30, 2023	S-3	As filed with the Securities and Exchange Commission on August 30, 2023 Table of Contents As filed with the Securities and Exchange Commission on August 30, 2023 Registration No.
August 30, 2023	EX-4.7	Description of Securities. ** EXHIBIT 4.7 SOLIGENIX, INC. DESCRIPTION OF SECURITIES The following description of the terms of our securities is not complete and is qualified in its entirety by reference to our Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and our Bylaws, as amended (the “Bylaws”), both of which are filed as exhibits to our Annual Reports on Form 10-K. Under our Certificate of In
August 21, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐TRANSITION REPORT PURSUANT TO SEC Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14778 SOLIGENIX
August 14, 2023	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-14778 CUSIP NUMBER: 834223 505 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: June 30, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in the form shall be construed to imply that the Commission has verified any information contained herein.
August 7, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement. ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitiv
August 7, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(
July 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 7, 2023 Commission File No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 7, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incorp
June 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2023 Commission File No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incor
May 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 23, 2023 Commission File No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 23, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incorp
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐TRANSITION REPORT PURSUANT TO SE Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14778 SOLIGENI
May 9, 2023	EX-99.2	Soligenix Announces Closing of $8.5 Million Public Offering EXHIBIT 99.2 Soligenix Announces Closing of $8.5 Million Public Offering Princeton, NJ, May 9, 2023 – Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the closing of its previously announced public offering of 6,538,500
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2023 Commission File No. 0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incorpo
May 9, 2023	EX-99.1	Soligenix Announces Pricing of $8.5 Million Public Offering EXHIBIT 99.1 Soligenix Announces Pricing of $8.5 Million Public Offering Princeton, NJ, May 5, 2023 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its public offering of 6,538,500 shares of common stock (
May 8, 2023	424B4	2,301,500 Shares of Common Stock Pre-Funded Warrants to Purchase 4,237,000 Shares of Common Stock Common Warrants to Purchase 6,538,500 Shares of Common Stock 4,237,000 shares of Common Stock Underlying the Pre-Funded Warrants 6,538,500 shares of Com Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Statement No. 333-271049 Prospectus 2,301,500 Shares of Common Stock Pre-Funded Warrants to Purchase 4,237,000 Shares of Common Stock Common Warrants to Purchase 6,538,500 Shares of Common Stock 4,237,000 shares of Common Stock Underlying the Pre-Funded Warrants 6,538,500 shares of Common Stock Underlying the Common Warrants We are of
May 4, 2023	CORRESP	Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 May 4, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Soligenix, Inc. Registration Statement on Form S-1 File No. 333-271049 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933 and on behalf of Soligenix, Inc. (the “Com
May 4, 2023	S-1/A	As filed with the Securities and Exchange Commission on May 4, 2023. Table of Contents As filed with the Securities and Exchange Commission on May 4, 2023.
May 3, 2023	EX-99.1	Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors Strengthens regulatory and orphan drug development expertise EXHIBIT 99.1 Soligenix Announces Appointment of Timothy R. Coté, M.D. to its Board of Directors Strengthens regulatory and orphan drug development expertise Princeton, NJ – May 3, 2023 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ann
May 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2023 Commission File No. 0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incorpo
May 1, 2023	EX-99.1	Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease Phase 2/3-Ready Orphan Disease Program Complements Company’s Existing Late-Stage Rare Disease Pipelin EXHIBIT 99.1 Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease Phase 2/3-Ready Orphan Disease Program Complements Company’s Existing Late-Stage Rare Disease Pipeline PRINCETON, NJ – May 1, 2023 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused
May 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2023 Commission File No. 0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incorpo
April 20, 2023	EX-4.2	Form of Common Warrant. * Exhibit 4.2 WARRANT TO PURCHASE SHARES OF COMMON STOCK SOLIGENIX, INC. Warrant Shares: Original Issuance Date: April [•], 2023 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the d
April 20, 2023	EX-1.1	Form of Placement Agent Agreement. * Exhibit 1.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 April [•], 2023 Soligenix, Inc. Attention: Christopher J. Schaber, President and Chief Executive Officer 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 Re: Placement Agent Agreement Dear Dr. Schaber: Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Gl
April 20, 2023	EX-4.3	Form of Common Warrant (incorporated by reference to Exhibit 4.3 to the Company’s Registration Statement on Form S-1/A (File No. 333-271049) filed on April 20, 2023). Exhibit 4.3 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK SOLIGENIX, INC. Warrant Shares: Original Issuance Date: April [•], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any
April 20, 2023	EX-4.4	Form of Securities Purchase Agreement. * Exhibit 4.4 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April [•], 2023, between Soligenix, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set for
April 20, 2023	S-1/A	As filed with the Securities and Exchange Commission on April 19, 2023. Table of Contents As filed with the Securities and Exchange Commission on April 19, 2023.
April 19, 2023	CORRESP	NEW YORK WASHINGTON, DC SAN FRANCISCO SILICON VALLEY SAN DIEGO LOS ANGELES FORT WORTH NEW YORK LONDON SINGAPORE PHILADELPHIA CHICAGO WASHINGTON, DC SAN FRANCISCO SILICON VALLEY SAN DIEGO LOS ANGELES BOSTON HOUSTON DALLAS FORT WORTH AUSTIN FIRM and AFFILIATE OFFICES HANOI HO CHI MINH CITY SHANGHAI ATLANTA BALTIMORE WILMINGTON MIAMI BOCA RATON PITTSBURGH NEWARK LAS VEGAS CHERRY HILL LAKE TAHOE MYANMAR ALLIANCES IN MEXICO www.
April 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 19, 2023 Commission File No UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 19, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of inco
April 19, 2023	EX-10.1	First Amendment to Loan and Security Agreement, dated April 19, 2023 (incorporated by reference to Exhibit 10.1 included in our current report on Form 8-K filed on April 19, 2023). EXHIBIT 10.1 FIRST AMENDMENT TO THE LOAN AGREEMENT This First Amendment (the “First Amendment”) to the Loan and Security Agreement, dated as of April 19, 2023 (the “Agreement”), by and between Soligenix, Inc., a corporation incorporated in the State of Delaware, and each of its Subsidiaries from time to time party hereto, including the Subsidiaries set forth on Schedule I to the Agreement (collect
April 14, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 14, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of inco
April 14, 2023	EX-99.1	Soligenix Provides Regulatory Update on HyBryte™ EXHIBIT 99.1 Soligenix Provides Regulatory Update on HyBryte™ Princeton, NJ – April 14, 2023 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company convened a Type A Meeting with the United States (U.S.) Food a
April 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 6, 2023 Commission File No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 6, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of incor
March 31, 2023	EX-21.1	Subsidiaries of the Company. * EXHIBIT 21.1 SUBSIDIARIES OF SOLIGENIX, INC. The following represents a list of Soligenix, Inc.’s subsidiaries: Name Ownership State of Incorporation Enteron Pharmaceuticals, Inc. 100.00 % Delaware Orasomal Technologies Inc. 75.30 % Delaware Soligenix BioPharma Canada Incorporated 100.00 % Canada Soligenix UK Limited 100.00 % United Kingdom Soligenix NE B.V. 100.00 % Netherlands Soligenix Biopharm
March 31, 2023	S-1	Power of Attorney. * S-1 1 tmb-20230331xs1.htm S-1 Table of Contents As filed with the Securities and Exchange Commission on March 31, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLIGENIX, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 41-1505029 (State or Other Jurisdict
March 31, 2023	EX-FILING FEES	Filing Fee Table. * Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Soligenix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1) Fee Rate Amount of Registration Fee Fees to be paid Equity Common Stock (2)
March 31, 2023	EX-21.1	Subsidiaries of the Company. * EXHIBIT 21.1 SUBSIDIARIES OF SOLIGENIX, INC. The following represents a list of Soligenix, Inc.’s subsidiaries: Name Ownership State of Incorporation Enteron Pharmaceuticals, Inc. 100.00 % Delaware Orasomal Technologies Inc. 75.30 % Delaware Soligenix BioPharma Canada Incorporated 100.00 % Canada Soligenix UK Limited 100.00 % United Kingdom Soligenix NE B.V. 100.00 % Netherlands Soligenix Biopharm
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Fiscal Year Ended December 31, 2022 ☐TRANSITION REPORT PURSUAN Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Fiscal Year Ended December 31, 2022 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File No. 001-14778 SOL
March 31, 2023	EX-4.1	Exhibit 4.1 EX-4.1 2 sngx-20221231xex4d1.htm EX-4.1 EXHIBIT 4.1 SOLIGENIX, INC. DESCRIPTION OF SECURITIES The following description of the terms of our securities is not complete and is qualified in its entirety by reference to our Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and our Bylaws, as amended (the “Bylaws”), both of which are filed as exhibits to our Annual Reports o
February 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 21, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
February 14, 2023	EX-99.1	Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma Soligenix intends to seek guidance from the FDA on how to further advance HyBryte™ towards potential approval EXHIBIT 99.1 Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma Soligenix intends to seek guidance from the FDA on how to further advance HyBryte™ towards potential approval Princeton, NJ – February 14, 2023 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused
February 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2023 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
February 9, 2023	EX-99.1	Soligenix Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on February 10, 2023 EXHIBIT 99.1 Soligenix Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on February 10, 2023 PRINCETON, N.J., February 9, 2023 /PRNewswire/ – Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today annou
February 9, 2023	EX-3.1	Certificate of Amendment to Second Amended and Restated Certificate of Incorporation of Soligenix, Inc. (incorporated by reference to Exhibit 3.1 included in our current report on Form 8-K filed on February 9, 2023). EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION THE UNDERSIGNED, being a duly appointed officer of Soligenix, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the Delaware General Corporation Law of the State of Delaware (the “DGCL”), for the purpose of amending the Corporation’s Second Amended and Restated Certi
February 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 8, 2023 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 8, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of in
January 11, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
January 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2023 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2023 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of in
January 6, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
December 27, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2022 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2022 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
December 27, 2022	EX-3.1	Certificate of Designation of the Series D Preferred Stock of the Company dated December 27, 2022 (incorporated by reference to Exhibit 3.1 to our registration statement on Form 8-A filed on December 27, 2022). EXHIBIT 3.1 SOLIGENIX, INC. CERTIFICATE OF DESIGNATION OF SERIES D PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware The undersigned does hereby certify, on behalf of Soligenix, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “Board of Directors”), in acc
December 27, 2022	8-A12G	Certificate of Designation of the Series D Preferred Stock of the Company dated December 27, 2022 (incorporated by reference to Exhibit 3.1 to our registration statement on Form 8-A filed on December 27, 2022). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Soligenix, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1505029 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 29 Emmo
December 27, 2022	EX-99.1	Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock EX-99.1 2 tmb-20221221xex99d1.htm EX-99.1 EXHIBIT 99.1 Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock Princeton, NJ – December 23, 2022 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announc
December 23, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 20, 2022 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 20, 2022 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
December 23, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?
December 19, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2022 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2022 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
December 19, 2022	EX-99.1	Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis Study HPN-PSR-01 opens patient enrollment EXHIBIT 99.1 Soligenix Initiates Phase 2 Clinical Trial of SGX302 (synthetic hypericin) for the Treatment of Mild-to-Moderate Psoriasis Study HPN-PSR-01 opens patient enrollment PRINCETON, NJ – December 19, 2022 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is
December 15, 2022	EX-99.1	Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma EXHIBIT 99.1 Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma Princeton, NJ – December 15, 2022 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today
December 15, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 15, 2022 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 15, 2022 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
November 18, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2022 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 16, 2022 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
November 16, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
November 15, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
November 14, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 ☐TRANSITION REPORT PURSUANT T Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-14778 SOLI
November 9, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
October 28, 2022	EX-FILING FEES	Calculation of Filing Fee Table. * EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Soligenix, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, par value $0.0
October 28, 2022	S-8	As filed with the Securities and Exchange Commission on October 28, 2022. As filed with the Securities and Exchange Commission on October 28, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SOLIGENIX, INC. (Exact name of registrant as specified in its charter) Delaware 41-1505029 (State or other jurisdiction of incorporation or organization) (I.R.S. Emplo
October 27, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 27, 2022 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 27, 2022 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of in
October 27, 2022	EX-99.1	Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses EXHIBIT 99.1 Soligenix Invited to Submit BARDA Contract Proposal for Development of Thermostabilized Subunit Vaccines for Sudan Ebola and Marburg Viruses ● Emerging infectious diseases where no protective vaccines are currently available ● SuVax™ targets Sudan ebolavirus, origin of a current disease outbreak in Uganda Princeton, NJ – October 27, 2022 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or
October 25, 2022	EX-99.1	Soligenix Announces Formation of Psoriasis Medical Advisory Board Phase 2a clinical study in mild-to-moderate psoriasis initiating in December 2022 EXHIBIT 99.1 Soligenix Announces Formation of Psoriasis Medical Advisory Board Phase 2a clinical study in mild-to-moderate psoriasis initiating in December 2022 Princeton, NJ – October 25, 2022 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical
October 25, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 25, 2022 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 25, 2022 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of in
October 20, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 19, 2022 Commission File UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 19, 2022 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of in
October 20, 2022	EX-99.1	Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting ● Meeting adjourned to November 17, 2022, at 9:00 a.m., Eastern Time ● Soligenix encourages all stockholders as of record July 25, 2022, who have not yet voted, EXHIBIT 99.1 Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting ● Meeting adjourned to November 17, 2022, at 9:00 a.m., Eastern Time ● Soligenix encourages all stockholders as of record July 25, 2022, who have not yet voted, to vote by 11:59 p.m., Eastern Time on November 16, 2022 Princeton, NJ – October 20, 2022 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or
October 5, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
September 23, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 22, 2022 Commission File No. 001-14778 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction
September 23, 2022	EX-99.1	Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting ● Meeting adjourned to October 19, 2022, at 9:00 a.m., Eastern Time ● Soligenix encourages all stockholders of record at the close of business on EXHIBIT 99.1 ? Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting ? ? Meeting adjourned to October 19, 2022, at 9:00 a.m., Eastern Time ? Soligenix encourages all stockholders of record at the close of business on July 25, 2022 who have not yet voted, to vote by 11:59 p.m., Eastern Time on October 18, 2022 ? Princeton, NJ ? September 23, 2022 ?
September 23, 2022	EX-10.1	Soligenix, Inc. 2015 Equity Incentive Plan, as amended on June 18, 2017, September 27, 2018, September 6, 2019 and September 22, 2022. EXHIBIT 10.1 SOLIGENIX, INC. 2015 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS ON APRIL 2, 2015 (as amended on June 18, 2017, September 27, 2018, September 6, 2019 and September 22, 2022) The purpose of the Soligenix, Inc. 2015 Equity Incentive Plan (the ?Plan?) is to advance the interests of Soligenix, Inc. by enhancing its ability to attract and retain employees and other persons who
September 13, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive
August 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 ☐TRANSITION REPORT PURSUANT TO SEC Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 9, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
August 5, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-
July 26, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-
July 13, 2022	8-K	Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 6, 2022 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of in
May 13, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 ☐TRANSITION REPORT PURSUANT TO SE Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 29, 2022	EX-21.1	Subsidiaries of the Company. * EXHIBIT 21.1 ? SUBSIDIARIES OF SOLIGENIX, INC. ? The following represents a list of Soligenix, Inc.?s subsidiaries: ? ? ? ? ? ? ? Name Ownership State of Incorporation Enteron Pharmaceuticals, Inc. ? 100.00 % Delaware ? Orasomal Technologies Inc. ? 75.30 % Delaware ? Soligenix BioPharma Canada Incorporated ? 100.00 % Canada ? Soligenix UK Limited ? 100.00 % United Kingdom ? Soligenix NE B.V. ? 100
March 29, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Fiscal Year Ended December 31, 2021 ☐TRANSITION REPORT PURSUAN Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 29, 2022	EX-4.4	Description of Securities. * EXHIBIT 4.4 ? SOLIGENIX, INC. DESCRIPTION OF SECURITIES ? The following description of the terms of our securities is not complete and is qualified in its entirety by reference to our Certificate of Incorporation, as amended (the ?Certificate of Incorporation?), and our Bylaws, as amended (the ?Bylaws?), both of which are filed as exhibits to our Annual Reports on Form 10-K. ? Under our Certificat
December 23, 2021	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): December 20, 2021 ? Commission File No. 001-14778 ? Soligenix, Inc. (Exact name of small business issuer as specified in its charter) ? ? ? ? DELAWARE ? 41-1505029 (State
November 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 ☐TRANSITION REPORT PURSUANT T Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 29, 2021	8-K	Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 29, 2021 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction o
September 24, 2021	8-K	Submission of Matters to a Vote of Security Holders ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 23, 2021 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction
September 20, 2021	8-K	Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): September 16, 2021 ? Commission File No. 001-14778 ? Soligenix, Inc. (Exact name of small business issuer as specified in its charter) ? ? ? ? DELAWARE ? 41-1505029 (State
September 20, 2021	EX-99.1	Soligenix to Advance Synthetic Hypericin Development in Psoriasis Exhibit 99.1 ? ? Soligenix to Advance Synthetic Hypericin Development in Psoriasis ? ? Validated clinical pharmacology and positive psoriasis proof-of-concept clinical study with synthetic hypericin sets stage for pipeline expansion ? Plan to initiate follow-on Phase 2a clinical study in mild-to-moderate psoriasis ? Psoriasis affects 60-125 million people worldwide ? Princeton, NJ ? September 16,
September 17, 2021	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): September 16, 2021 ? Commission File No. 001-14778 ? Soligenix, Inc. (Exact name of small business issuer as specified in its charter) ? ? ? ? DELAWARE ? 41-1505029 (State
August 27, 2021	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): August 25, 2021 ? Commission File No. 001-14778 ? Soligenix, Inc. (Exact name of small business issuer as specified in its charter) ? ? ? ? DELAWARE ? 41-1505029 (State or
August 13, 2021	424B5	$30 Million Soligenix, Inc. Common Stock Table of Contents ? Filed Pursuant to Rule 424(b)(5) Registration No. 333-239928 PROSPECTUS SUPPLEMENT (To prospectus dated August 13, 2021) $30 Million Soligenix, Inc. Common Stock We have entered into an at-the-market offering agreement (the ?distribution agreement?), with B. Riley Securities, Inc. (?B. Riley Securities?), dated August 11, 2017 and amended August 28, 2020, relating to shares of
August 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 ☐TRANSITION REPORT PURSUANT TO SEC Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 13, 2021	8-K	Financial Statements and Exhibits, Other Events ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 ? Date of Report (Date of Earliest Event Reported): August 13, 2021 ? Commission File No. 001-14778 ? Soligenix, Inc. (Exact name of small business issuer as specified in its charter) ? ? ? ? DELAWARE ? 41-1505029 (State or
August 10, 2021	DEF 14A	Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on August 10, 2021; UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement. ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definit
August 10, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement. ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2
May 18, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-14778 CUSIP NUMBER: 834223307 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Period Ended: Nothing in the form shall be construed to imply that the Commission has verified any information contained herein.
May 18, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-16929 SOLIGENIX, INC. (Exact n
May 7, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2021 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) Delaware 41-1505029 (State or other jurisdiction of incorpo
April 13, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 13, 2021 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) Delaware 41-1505029 (State or other jurisdiction of inco
April 13, 2021	EX-99.1	Soligenix Announces Presentations at Prominent Scientific Conferences Key Data Outcomes Presented for HyBryte™ and CiVax™ Exhibit 99.1 Soligenix Announces Presentations at Prominent Scientific Conferences Key Data Outcomes Presented for HyBryte? and CiVax? Princeton, NJ ? April 13, 2021 ? Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today planne
March 30, 2021	EX-21.1	Subsidiaries of the Company. * EXHIBIT 21.1 SUBSIDIARIES OF SOLIGENIX, INC. The following represents a list of Soligenix, Inc.?s subsidiaries: Name Ownership State of Incorporation Enteron Pharmaceuticals, Inc. 100.00 % Delaware Orasomal Technologies Inc. 75.30 % Delaware Soligenix BioPharma Canada Incorporated 100.00 % Canada Soligenix UK Limited 100.00 % United Kingdom Soligenix NE B.V. 100.00 % Netherlands
March 30, 2021	10-K	Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the Fiscal Year Ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File No. 000-16929 SOLIGENIX, INC. (Exact na
March 30, 2021	EX-4.6	Description of Securities. * EXHIBIT 4.6 SOLIGENIX, INC. DESCRIPTION OF SECURITIES The following description of the terms of our securities is not complete and is qualified in its entirety by reference to our Certificate of Incorporation, as amended (the ?Certificate of Incorporation?), and our Bylaws, as amended (the ?Bylaws?), both of which are filed as exhibits to our Annual Reports on Form 10-K. Under our Certificate of I
January 27, 2021	CORRESP	- Soligenix, Inc. 29 Emmons Drive, Suite B-10 Princeton, NJ 08540 January 27, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Soligenix, Inc. Registration Statement on Form S-3 Filed January 15, 2021 File No. 333-252153 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933 and on behalf
January 26, 2021	EX-99.1	Investor Presentation – “U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma.” Exhibit 99.1
January 26, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 26, 2021 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of in
January 15, 2021	S-3	- REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on January 15, 2021 Registration No.
December 22, 2020	EX-99.2	Soligenix Corporate Update Conference Call December 22, 2020 8:30 a.m. Eastern Time EXHIBIT 99.2 Soligenix Corporate Update Conference Call December 22, 2020 8:30 a.m. Eastern Time Operator Welcome to the Soligenix Corporate Update conference call. At this time all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a Q&A session with the questions submitted by email prior to the call. As a reminder, this is a timed conference call today.
December 22, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 22, 2020 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
December 22, 2020	EX-99.1	Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients Company to Host Investor Conference Call Today at 8:30AM EST EXHIBIT 99.1 Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients Company to Host Investor Conference Call Today at 8:30AM EST Princeton, NJ – December 22, 2020 – Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing pro
December 16, 2020	EX-10.2	Third Amendment to Employment Agreement dated as of December 10, 2020, between Soligenix, Inc. and Christopher J. Schaber, PhD. (incorporated by reference to Exhibit 10.2 included in our current report on Form 8-K filed on December 16, 2020). ** Exhibit 10.2 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment to Employment Agreement (the “Amendment”) is made and entered into as of December 10, 2020 by and between Soligenix, Inc., a Delaware corporation having a place of business at 29 Emmons Drive, Suite B-10, Princeton, NJ 08540 (the “Corporation”), and Christopher J. Schaber, Ph.D. (the “Employee”). RECITALS WHEREAS, the Corpor
December 16, 2020	EX-99.1	Soligenix Announces $20 Million Strategic Convertible Debt Financing Agreement with Pontifax Medison Debt Financing ● Extends cash runway through 2022 ● Debt can be converted into equity at a price of $4.10 per share Exhibit 99.1 Soligenix Announces $20 Million Strategic Convertible Debt Financing Agreement with Pontifax Medison Debt Financing ● Extends cash runway through 2022 ● Debt can be converted into equity at a price of $4.10 per share Princeton, NJ – December 16, 2020 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercial
December 16, 2020	EX-10.1	Loan and Security Agreement, dated December 15, 2020. (incorporated by reference to Exhibit 10.1 included in our current report on Form 8-K filed on December 16, 2020). Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of December 15, 2020 and is entered into by and between Soligenix, Inc., a corporation incorporated in the State of Delaware, and each of its Subsidiaries from time to time party hereto, including the Subsidiaries set forth on Schedule I hereto (collectively referred to as “Borrower”), Pontifax Medison F
December 16, 2020	EX-4.1	Registration Rights Agreement, dated December 15, 2020 by and among Soligenix, Inc. and the other parties named therein (incorporated by reference to Exhibit 4.1 included in our current report on Form 8-K filed on December 16, 2020). Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of December 15, 2020 by and among Soligenix, Inc., a corporation incorporated in the State of Delaware (the “Company”), and the “Lenders” named in that certain Loan and Security Agreement by and among the Company and the Lenders, dated December 15, 2020 (the “Loan Agreement”)
December 16, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 10, 2020 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) Delaware 41-1505029 (State or other jurisdiction of i
December 3, 2020	EX-3.1	Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of amendment number 1 to current report on Form 8-K filed on December 3, 2020). Exhibit 3.1 CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION THE UNDERSIGNED, being a duly appointed officer of Soligenix, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the Delaware General Corporation Law of the State of Delaware (the “DGCL”), for the purpose of amending the Corporation’s Second Amended and Restated Certi
December 3, 2020	8-K/A	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year - AMENDMENT NO. 1 TO FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 27, 2020 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of
November 25, 2020	DEFA14A	- CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 23, 2020 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
November 25, 2020	8-K	Submission of Matters to a Vote of Security Holders - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 23, 2020 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of i
November 12, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-16929 SOLIGENIX, INC. (Exa
November 12, 2020	EX-10.1	Third Extension and Amendment to Lease dated July 7, 2020 between CPP II LLC and Soligenix, Inc. (incorporated by reference to Exhibit 10.1 included in our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020). Exhibit 10.1 THIRD EXTENSION AND AMENDMENT TO LEASE THIS THIRD EXTENSION AND AMENDMENT TO LEASE made as of this 7th day of July 2020, by and between CPP II LLC, a Delaware limited liability company, with an address at c/o Oestreicher Properties Inc., 430 Park Avenue, 5th Floor, New York, New York 10022(“Landlord”), and SOLIGENIX, INC., a corporation organized and existing under the laws of the Sta
November 6, 2020	DEF 14A	- DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitiv
October 23, 2020	PRE 14A	- PELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement. ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitiv
September 18, 2020	EX-3.1	Certificate of Amendment to Second Amended and Restated Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION THE UNDERSIGNED, being a duly appointed officer of Soligenix, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the Delaware General Corporation Law of the State of Delaware (the “DGCL”), for the purpose of amending the Corporation’s Second Amended and Restated Certi
September 18, 2020	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 16, 2020 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) DELAWARE 41-1505029 (State or other jurisdiction of
September 10, 2020	EX-99.2	COVID - 19 Landscape and Applications NASDAQ: SNGX Forward - Looking Statements This presentation contains forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements re Exhibit 99.2 COVID - 19 Landscape and Applications NASDAQ: SNGX Forward - Looking Statements This presentation contains forward - looking statements . All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products and product candidates and their
September 10, 2020	8-K	Financial Statements and Exhibits, Other Events - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 10, 2020 Commission File No. 000-16929 Soligenix, Inc. (Exact name of small business issuer as specified in its charter) Delaware 41-1505029 (State or other jurisdiction of

SNGX / Soligenix, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings